Recent Updates
Recently added Catalysts

B-Cell Acute Lymphoblastic Leukemia: two biotech companies racing to a treatment

OncologyOrphan cornerData as of 2026-09-04

Competitors2in the clinic
Median market cap$221Muniverse median $1.20B
Allocated capital$92M$443M competing
Phase 3 or filed00 mid, 2 early
Pure plays0this indication only
Capital rank275/299crowding rank 101

B-Cell Acute Lymphoblastic Leukemia is a two-horse race: Cellectis S.A. (CLLS, $239M) against Precision BioSciences (DTIL, $203M).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $92M of allocated capital sits on the pair.

CLLS carries 54% of the $443M competing here, so the pair is far from evenly matched.

$92M of allocated capital sits in B-Cell Acute Lymphoblastic Leukemia, ranking it 275th of 299 indications by the money committed to it.

Companies developing drugs for B-Cell Acute Lymphoblastic Leukemia 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CLLSCellectis S.A.CLLS52Phase 12$239MNo3 31 Dec 2026
DTILPrecision BioSciencesCD19 and CD22 targeted prime CAR-T cellsPhase 12$203MNo16 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. CLLS holds 54% of the $443M competing in this indication.

Why B-Cell Acute Lymphoblastic Leukemia is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. B-Cell Acute Lymphoblastic Leukemia has 2 competitors and a median of $221M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Low-Grade Serous Ovarian Carcinoma1 company · $90M · median $723MUncontestedEndometrioid Carcinoma1 company · $90M · median $723MUncontestedHigh-grade Serous Ovarian Cancer1 company · $98M · median $295MUncontestedRelapsed/Refractory Non-Hodgkin's Lymphoma1 company · $117M · median $351MUncontestedWell-differentiated Pancreatic Neuroendocrine Tumor1 company · $119M · median $356MUncontestedRecurrent Cutaneous T-Cell Lymphoma1 company · $119M · median $356MUncontestedAdenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1 company · $64M · median $129MUncontestedMetastatic Urothelial Cancer1 company · $54M · median $214MUncontested

B-Cell Acute Lymphoblastic Leukemia pipeline questions

Which biotech companies are developing drugs for B-Cell Acute Lymphoblastic Leukemia?

Cellectis S.A. (CLLS, CLLS52, Phase 1); Precision BioSciences (DTIL, CD19 and CD22 targeted prime CAR-T cells, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in B-Cell Acute Lymphoblastic Leukemia.

How advanced is the B-Cell Acute Lymphoblastic Leukemia pipeline?

Of the 2 clinical-stage programmes in B-Cell Acute Lymphoblastic Leukemia, 0 are in Phase 3 or filed, 0 are in mid-stage development and 2 are in early-stage development.

Which company leads the B-Cell Acute Lymphoblastic Leukemia field?

CLLS is the largest developer in B-Cell Acute Lymphoblastic Leukemia, holding 54% of the $443M of market capitalisation competing in the indication. The median competitor is worth $221M.

When is the next B-Cell Acute Lymphoblastic Leukemia catalyst?

The next dated catalyst in B-Cell Acute Lymphoblastic Leukemia is CLLS on 31 Dec 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map